Neovasc — Investor Presentation (June 2009)
19 slides from Neovasc's investor presentation, June 2009
Slide 1: Neovasc Inc.
Neovasc Inc. June 2009 Alexei Marko, CEO Chris Clark, CFO Brian McPherson, COO
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-loo
Slide 3: Neovasc at-a-Glance
Neovasc at-a-Glance Neovasc develops, manufactures and markets innovative vascular and surgical devices. Our products include the Neovasc Reducer™ for refractory angina and Peripatch™ implantable surgical tissue. We also offer pericardial tissue processing, vascular product development, design and m
Slide 4: Key Products
Key Products Neovasc Reducer™ Treatment for Refractory Angina PeriPatch™ Implantable Surgical Tissue 4
Slide 5: Neovasc Reducer
Neovasc Reducer Treats “Refractory Angina” • Inadequate blood flow to heart muscle that can no longer be managed through conventional drug, catheter or surgical therapy • Caused by advanced disease of the arteries feeding the heart muscle • Causes debilitating chest pain • No current treatment • 1 m
Slide 6: Reducer Treatment
Reducer Treatment Patient with Angina Patient with Reducer Oxygenated blood feeds heart muscle through “coronary arteries” inflow Improved penetration of Poor blood flow oxygenated into heart muscle. blood to feed Severe angina pain. heart muscle. Reduced angina pain. outflow Reducer implanted to re
Slide 7: Reducer Procedure
Reducer Procedure • Implanted using standard catheter-based techniques (non-surgical) • Procedure time < 20 minutes • Access is through venous system, so minimal risk of puncture site complications • Patient typically discharged within 24 hours • Provides a new treatment for an untreatable patient 7
Slide 8: Reducer Clinical Data
Reducer Clinical Data • Compelling clinical data from first human trial (15 patients, 3 centers) • Six month data published in JACC, May 2007: – No device-related adverse events or complications – Significant improvement of refractory angina symptoms in majority of subjects • Three year follow-up da
Slide 9: Reducer Commercialization
Reducer Commercialization • Development completed and product has been transferred to manufacture • Filing for EU approval (CE-Mark) in 2009 • Once CE mark is received will pilot launch in select European centers • US pilot clinical trial will be initiated in 2009 • US FDA approval process (PMA) wil
Slide 10: PeriPatch Technology
PeriPatch Technology • Specially treated bovine, equine and porcine pericardial tissue • Proprietary treatment process creates implantable, biocompatible tissue that retains physical characteristics of natural tissue • Initially developed for implantable heart valve applications • Adapted for genera
Slide 11: PeriPatch Products
PeriPatch Products • Tissue available in a variety of shapes and sizes • Configure as a stand-alone surgical patch or incorporate into other devices • Marketed through distributors and strategic partners 11
Slide 12: PeriPatch Products: Vascular Strip
PeriPatch Products: Vascular Strip • Specially shaped strips used for vascular repair procedures • Distributed exclusively by LeMaitre Vascular, a leading manufacturer and supplier of products to vascular surgeons • Primary target is “carotid endarterectomies” (180k cases/yr in US) 12
Slide 13: Peripatch Products: 3rd Party Solutions
Peripatch Products: 3rd Party Solutions Neovasc supplies tissue to 3rd parties for incorporation into devices such as heart valves and covered stents. – Neovasc is a leading supplier of heart valve leaflets for minimally invasive valve companies – Neovasc provides pericardial tissue processing, vasc
Slide 14: Under Development – MatrixBP Tissue
Under Development – MatrixBP Tissue • Remodelable surgical patch for soft tissue reinforcement and repair • Tissue promotes neovascularization from host tissue • US / EU approval expected in late 2009 Primarily targets non-vascular applications • Rotator cuff and tendon repair • Dural repair • Urina
Slide 15: Financial Projections
Financial Projections Break Even 4,000 3,000 2,000 1,000 Revenue $000s Contribution - Expenses FY8Q3 FY9Q1 FY9Q3 FY10Q1 FY10Q3 FY11Q1 FY11Q3 -1,000 EBITDA -2,000 -3,000 -4,000 Quarter 15
Slide 16: Clinical Advisors
Clinical Advisors Our Advisors include leading practitioners and opinion leaders Dr. David Allie Dr. Gary Ansel Dr. Shmuel Banai Dr. Craig Walker Dr. Martin Leon Dr. Robert Bonow Dr. Jorge Saucedo Dr. Chris White Dr. Elezar Edelman Dr. Robert Tahara Dr. Ken Rosenfeld Dr. Tim Henry 16
Slide 17: Management and Board
Management and Board Executive Management Board of Directors Alexei Marko - CEO and board member Paul Geyer (former CEO, Mitroflow) Chris Clark - CFO Steven Rubin (Frost Group, OPKO) Brian McPherson - COO Dr. Jane Hsiao (Frost Group, OPKO) Boaz Lifschitz (Peregrine Ventures) Dr. William O’Neill (Car
Slide 18: Capitalization & Trading
Capitalization & Trading • 27.4 million (issued and outstanding) Shares outstanding • 36.6 million (fully diluted) Public listings • TSX-V NVC • Frost Group (Dr. Philip Frost) Key investors • Peregrine Ventures • Company management • ~70% of shares held by management and insiders Float • Float ~ 8 m
Slide 19: Conclusion
Conclusion • Growing company with early revenues from multiple sources and strong product pipeline • Products address clear and growing needs for physicians and medical industry partners • Experienced management team, board and advisors • Lean operation, focused on building value and achieving posit